MedTrace Logo

Dosing of Carcinogenic Complexes After Anesthesia With Intrathecal Hyperbaric Prilocaine.

NCT03642301 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2019-05-22

No results posted yet for this study

Summary

The prilocaine is a very common local anesthetic that has the disadvantage of being metabolized to o-toluidine, a human carcinogen.

Hyperbaric 2% prilocaine (HP), recently developped, is increasingly used for spinal anesthesia in ambulatory surgery. But the formation of carcinogenic metabolites induced by the hyperbaric prilocaine is not yet known. The aim of this study is to investigate whether the intrathecal administration of 50 mg hyperbaric prilocaine induces also the formation of carcinogenic complexes such as urinary o-toluidine and hemoglobin adducts from o-toluidine in blood.

Conditions

  • Anesthesia

Sponsors & Collaborators

  • Ruhr University of Bochum

    collaborator OTHER

  • Hôpital de Braine-l'Alleud

    collaborator OTHER

  • Centre Hospitalier Universitaire Saint Pierre

    lead OTHER

Principal Investigators

  • Emmanuel Guntz, MD · Université Libre de Bruxelles (ULB), Braine-l'Alleud Hospital

  • Panayota Kapessidou, MD,PhD · University Hospital Saint-Pierre (CHU Saint-Pierre), Université Libre de Bruxelles (ULB)

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-10
Primary Completion
2019-03-27
Completion
2019-03-27

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03642301 on ClinicalTrials.gov